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Evaluation of Quadrivalent HPV 6/11/16/18 Vaccine Efﬁ-
cacy Against Cervical Disease in Subjects with Prior
Vaccine HPV Type Infection
D. Ferris
Medical College of Georgia, Augusta, GA, USA
Objective: In the international clinical program for
the quadrivalent (types 6/11/16/18) HPV vaccine, 73% of
women aged 16—26 were na¨ıve to all vaccine HPV types.
In these women, prophylactic administration of the vaccine
was highly effective in preventing HPV 6/11/16/18-related
cervical disease. In contrast, the vaccine did not demon-
strate therapeutic efﬁcacy. At the time of vaccination, 15%
of women had evidence of past cleared infection with one
or more vaccine HPV types (seropositive and DNA negative).
Here we present an analysis in this group of women to deter-
mine the efﬁcacy of the HPV 6/11/16/18 vaccine against
new cervical disease related to the same vaccine HPV type
which had previously been cleared.
Materials and Methods: 18,150 women were enrolled in
1 of 3 large clinical studies. Data are representative of a
subset of these subjects who were HPV seropositive and
DNA negative at enrollment (for ≥1 vaccine type). In each
study, subjects were randomized in a 1:1 ratio to receive
HPV 6/11/16/18 vaccine or placebo at day 1, month 2 and
month 6. Procedures performed for efﬁcacy data evalua-
tion included detailed genital examination, Pap testing, and
collection of cervicovaginal specimens. Analyses of efﬁcacy
were carried out in a prophylactic population stratiﬁed by
HPV serology and cervical DNA status on day 1.
Results: Subjects were followed for an average of 44
months. Seven subjects in the placebo group developed
cervical disease related to a vaccine HPV type they had
previously encountered and cleared. No subject receiving
HPV 6/11/16/18 vaccine developed disease to a vaccine HPV
type to which they were seropositive and DNA negative at
enrolment (vaccine efﬁcacy: 100% (95% CI: 28.7, 100.0).
Conclusion: These results suggest that infection-elicited
antibodies may not provide complete protection over time,
and that HPV 6/11/16/18 vaccine may prevent recurrence
of disease with vaccine HPV types.
doi:10.1016/j.ijid.2008.05.376
19.031
The Effectiveness of the Universal Infant Immunization
Against Hepatitis B in Bulgaria
M. Kojouharova ∗, A. Kurchatova
National Centre of Infectious and Parasitic Diseases, Soﬁa,
Bulgaria
Background: Bulgaria is a country in an area of interme-
diate endemicity of Hepatitis B viral (HBV) infection, with
3-5% HBV carrier prevalence and more than 30% of the popu-
lation with serological evidence of HBV infection. Because of
the evidence of occurrence of perinatal transmission (up to
23.4% of carrier mothers were HBeAg positive), a strategy for
selective immunization of high risk newborns to HBV carrier
mothers was implemented from January 1988 to July 1991,
when Bulgaria was one of the ﬁrst countries having decided
to adopt routine universal infant HBV vaccination, starting
as early as August 1991. Since that time, the effectiveness
of Hepatitis B immunization programme has been subject
to a nation-wide, prospective surveillance. The aim of the
present study is to analyze the changes in HBV epidemiology
16 years after the start of the programme for routine infant
HBV vaccination.
Methods: The analysis is based on the data for age-
speciﬁc annual incidence of acute clinically manifested
cases of HBV infection, obtained from the National com-
municable disease surveillance system which is requiring
compulsory notiﬁcation and laboratory conﬁrmation of all
acute HBV cases. The data on immunization coverage are
obtained from the Immunization information system.
Results: Before the introduction of the immunization,
the incidence of HBV infection in newborns and children
1—3 years of age was 31.1 and 31.6 per 100 000, respec-
tively. The incidence was highest in persons 4—7, 15—19
and 20—29 years of age: 59.9; 50.0 and 50.2 per 100 000,
respectively. During 1988—1991, the period of selective
immunization, the HBV incidence declined (40.9%) only in
infants. The greatest decline of acute Hepatitis B in Bul-
garia occurred 16 years after the start of the universal
infant vaccination. Among children 0 to 14 years of age,
HBV incidence was 2.6 per 100 000 in 2007 and the decline
(94.2%) coincided with the increase of the cumulative num-
ber of immunized infants. As of 2007, a total of 1 068 240
children had been fully vaccinated with 3 doses of HBV vac-
cine.
Conclusion: To date, the immunization strategy focusing
on universal infant vaccination beginning at birth has been
implemented with considerable success in Bulgaria.
The introduced in 1992 immunization programme dra-
matically reduced the incidence of acute Hepatitis B in
targeted age groups; this effect will be fully achieved in
2011, when all adolescents up to 19 years of age will be
immunized.
doi:10.1016/j.ijid.2008.05.377
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Boutonneuse Fever Issues in Constantza County
S. Rugina
Ovidiu University, Constantza, Romania
Introduction: Boutonneuse fever is an eruptive disease
endemic in Mediterranean basin. Constantza, remain the
most important rickettsian endemic zone because the cli-
macterics conditions and the increased number of stray
dogs.
Material and methods: The diagnostic was made on clin-
ical and epidemiological dates.
Results: 80% of patients recognized the presence of the
dog, and 45% the bites or presence of the ticks. 78% of cases
were from urban environment. The adults were prevalent
affected 86%, 2:1 for women, children made easy form and
the adults’ medium. Few cases were severe, with neuro-
logical complications. The clinical evolution of the patients
with treatment was favorable, improvement of the illness
appeared after 3-4 days. The number of cases continuously
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increase, the situation of cases with Boutonneuse fever dur-
ing last 15 years were:
Year - (No. of cases) 1991 - (3); 1992 - (6); 1993 - (12);
1994 - (26); 1995 - (24); 1996 - (27); 1997 - (21); 1998 - (30);
1999 - (68); 2000 - (13); 2001 - (30); 2002 - (17); 2003 - (14);
2004 - (16); 2005 - (99); 2006 - (61); 2007 - (25)
Conclusions: The monthly distribution of this disease
reﬂects seasonality of this affection, according with max-
imum period of thick spreading and human contact with
them. The year 2001 as 2000 register in June, especially
July and August the pick of morbidity, according to period of
maximum spread of ticks and human contacts with them and
for these years temperatures over the multiannual average.
doi:10.1016/j.ijid.2008.05.378
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Surveillance of Adverse Events Following Immuniza-
tion (AEFI) with Human Papillomavirus (HPV) Vaccine in
Canada (Sep. 2006 — Dec. 2007)
J. Nkanza
Public Health Agency of Canada, Ottawa, Canada
Background: The Quadrivalent HP Recombinant Vaccine,
GardasilTM was approved in Canada in July 2006 and has been
in use since September 2006. Gardasil is offered to females
between 9 and 26 years of age. The aim of this vaccine is
to prevent the diseases associated with HPV types 6, 11,
16, 18 (cervical cancer and anogenital warts). Some juris-
dictions have already included this vaccine in their school
based immunization program.
Methods: All Adverse Event Following Immunization
reports received by the Public Health Agency of Canada
through passive and active surveillance programs were
reviewed and included in the analysis.
Results: A total of 148 reports of AEFI was received by the
Agency between September 2006 and December 2007, with a
reporting rate estimated at 38/100,000 doses distributed. In
majority of cases (97.4%) HPV vaccine was the only vaccine
given.
The age ranged from 10 to 45 years old with median at
18.0 and StD 5.8 years.
The most commonly reported AEFIs were injection site
pain (20%), other injection site reactions (8%), nausea
(8%); dizziness, headache, rash and vomiting (each 7.5%),
urticaria (7%); and diarrhea, fever, rash and syncope (each
6%). There were two reports of serious AEFIs - one anaphy-
lactic reaction and one encephalopathy.
Medical attention was sought by 51 cases (35%), including
4 hospitalizations, 10 emergency room visits and 37 outpa-
tient visits. The outcome was reported in 58 reports (40%),
of which 41 reported full recovery, 10 recovering, and 7
reported some residual effect at the time of reporting.
Conclusion: Gardasil is considered a safe vaccine in
Canada. AEFIs reported following this vaccine were mainly
minor injection site reactions and mild systemic events.
AEFI data collected through the Canadian active and pas-
sive surveillance programs have been consistent with the
data obtained from the pre-licensure clinical trials.
doi:10.1016/j.ijid.2008.05.379
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Safety and Reactogenicity of a 10-Valent Pneumo-
coccal Non-Typeable Haemophilus inﬂuenzae Protein
D-Conjugate Vaccine (PHiD-CV) in Filipino Infants
N. Bermal1,∗, E. Alberto1, M. Hernandez1, V. Pau2, A.
Fanic3, H. Bock4, I. Dieussaert3, L. Schuerman3
1 Research Institute for Tropical Medicine, Muntinlupa City,
Philippines
2 Bulihan Rural Health Unit (RHU), Bulihan, Silang Cavite,
Philippines
3 GlaxoSmithKline Biologicals, Rixensart, Belgium
4 GlaxoSmithKline Biologicals (Singapore), Singapore, Singa-
pore
Background: Safety and reactogenicity of the candidate
10-valent Pneumococcal non-typeable Haemophilus inﬂuen-
zae Protein D-conjugate vaccine (PHiD-CV, GlaxoSmithKline
Biologicals), designed to protect infants against pneumo-
coccal and non-typeable Haemophilus inﬂuenzae diseases,
were evaluated when co-administered with DTPw-HBV/Hib
and OPV vaccines at 6—10—14 weeks of age (EPI schedule)
in the Philippines.
Methods: In this double-blind, controlled study
(107007/NCT00344318), 400 healthy Filipino infants 6
to 12 weeks old were randomized (3:1) to receive either
PHiD-CV or licensed 7vCRM vaccine (PrevenarTM/PrevnarTM),
both co-administered with DTPw-HBV/Hib +OPV. Solicited
local (pain, redness, swelling), general (fever, drowsiness,
irritability, loss of appetite) and unsolicited symptoms as
well as serious adverse events (SAEs) were recorded after
each vaccination. Intensity was assessed on a scale from
1—3.
Results: The most frequently reported solicited local
grade 3 symptoms were pain following 9.4% of vaccine
doses in both groups and swelling following 9.3% (PHiD-
CV) and 8.1% (7vCRM) vaccine doses. Irritability was the
most frequently reported solicited general grade 3 symptom
following 2.9% (PHiD-CV) and 2.4% (7vCRM) vaccine doses.
Observed overall/dose incidence of fever (rectal temper-
ature ≥38 ◦C) was within the same range in both groups
(PHiD-CV: 60.9%; 7vCRM: 63.0%) with no cases of rectal fever
>40 ◦C. Seven infants reported at least one SAE: 6 in the
PHiD-CV group and 1 in the 7vCRM group. None of them
was assessed by the investigator to be causally related to
vaccination and all resolved without sequelae.
Conclusion: No clinically relevant differences were
observed between the safety and reactogenicity proﬁles of
PHiD-CV and 7vCRM vaccines.
doi:10.1016/j.ijid.2008.05.380
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A Study to Estimate the Incidence and Percentage of Vac-
cination Coverage of Measles in Under 5 Children in Slums
of Madipur, (West) Delhi
A. Choudhry
National Institute Of Communicable Diseases, New Delhi,
India
Background: Measles has been universally known as a
major child health problem and a killer of children mainly
